Seeking Alpha

StockMatusow

 
View as an RSS Feed
View StockMatusow's Articles BY TICKER:
  • Well-Known Activist Shareholder Pushing For Sale Of Identiv
    Mon, Dec. 22 INVE 6 Comments

    Summary

    • David Callan, a well-known activist who was involved with helping to facilitate the sales of Obagi, Solta, Sound Surgical and others, is now calling for Identiv to shop itself.
    • Callan makes several key points in which many we agree with. We also think now would be a good time for Identiv to explore strategic alternatives.
    • However, we think that Identiv is already in talks with suitors for acquisition and will be acquired soon. Nonetheless, we think it's positive for Callan to push for acquisition now.
  • Identiv Goes On The Record With NFC For Disney Infinity Toys: Star Wars Infinity Toys Likely Next
    Wed, Dec. 17 INVE 2 Comments

    Summary

    • Identiv's Chief financial officer Brian Nelson last week went on the record to confirm that Identiv has been supplying NFC technology for Disney Infinity toys.
    • Our due diligence lead us to believe this fact many months ago, but the company had not confirmed for a fact that it's behind the NFC technology for the toys.
    • We have since learned through our research that the company is likely to provide the same NFC technology for Disney's upcoming Star Wars infinity toys in 2015.
    • We have included the entire investor conference where Brian Nelson goes on record about the infinity toys along with additional information.
  • NFC Technology Integrated Into Smartphones Helps Pave The Road For Identiv
    Wed, Dec. 10 INVE 1 Comment

    Summary

    • Apple's iPhone 6 institutes Near Field Communication (NFC) for its payment system.
    • Before Apple adopted NFC for this use, the technology was seen as being in a kind of limbo.
    • Identiv is in a prime position to capitalize on the reinvigoration of NFC.
    • Identiv is one of the largest suppliers of NFC tags in the world, and provides these same tags for Disney's line of Infinity toys.
  • Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
    Tue, Nov. 25 CEMP 6 Comments

    Summary

    • Cempra Pharmaceuticals expects top-line data release for community acquired bacterial pneumonia by the end of Q1'15.
    • Cempra's Solithromycin is also designed to potentially treat a wide array of bacterial infections, perhaps placing its potential value at the top of the developmental antibacterial company list.
    • With Trius Pharma acquired by Cubist in late 2013, along with the very recent Tetraphase acquisition rumor buzz, Cempra is certain to join the fray if its data release proves.
  • Identiv's Post-Password Era Solutions Gaining Traction As Company Strengthens Financial Position
    Editors' Pick • Tue, Nov. 18 INVE 6 Comments

    Summary

    • Lately, we have seen many headlines about how large companies are experiencing security breaches that have resulted in sensitive customer information being exposed to theft.
    • Breaches included passwords that were hacked, and/or cyber thieves finding security weaknesses in companies' internal networks. Identiv offers best-in-class solutions to combat these types of security breaches.
    • In this article, we review the tech and Identiv's recent Q3 earnings, and show why the company is grossly undervalued and has strong upside potential.
  • Identiv's Q2 Earnings Show Strong Growth - Acquisition Likely At Some Point
    Thu, Aug. 14 INVE 8 Comments

    Summary

    • Late last year, Identiv brought in an entirely new senior management team to turn company around.
    • In Q4 2013 and Q1 2014, the company's new management took steps to reorganize its business structure.
    • Identiv's growth strategy is to partner with multiple large companies to unlock shareholder value. After listening to earnings call, I believe company will be acquired at some point in time.
    • Company Chief Executive Officer (CEO) Jason Hart believes the company to be worth $400M now, but has not realized this valuation because of missteps by prior management.
  • Identiv: An Internet Of Things Small-Cap Pick For Consideration
    Tue, Aug. 5 INVE 10 Comments

    Summary

    • The “Internet of things” is forecast to become a $7 to $10 trillion market by 2020. Also know as “IoT,” these three letters excite those in the tech field.
    • The riskiest, yet most rewarding investments in the market are small-cap companies with the potential to become much larger caps in time.
    • Microsoft, Apple and others started out as small-cap companies and became true investments which took many years for those who were vested to realize the large gains.
    • We believe we have found at least one company we feel will be a long-term winner because first and foremost it has new top-notch management captaining the ship.
  • Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release
    Wed, Jul. 23 FOLD 5 Comments

    Summary

    • One of the strongest investing strategies in the biotech sector is to follow what successful biotech funds are buying in large quantities.
    • Last year, we detailed some companies that a successful fund, the Baker Brothers LLC, bought. Many of their investments have been profitable to date.
    • In this write up, we focus on another successful fund, Perceptive Advisors, led by well-known investor Joseph Edelman.
  • Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment
    Tue, Jul. 8 HALO 11 Comments

    Summary

    • Halozyme and Baxter Pharma have a Food and Drug Administration (FDA) Advisory Committee (adcom) meeting coming up on July 31.
    • The adcom will give guidance on whether Halozyme's Biologics License Application (BLA) for its Human Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase (HyQvia) is acceptable in its new amended form.
    • We believe the chance is about 80% for a positive adcom outcome.
    • Additionally, Halozyme's proprietary PEGPH20 if ultimately FDA approved in time, would be a blockbuster treatment for Pancreatic Cancer, an open and large unmet need.
  • AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month
    Wed, Jul. 2 ACRX 29 Comments

    Summary

    • AcelRx develops Zalviso to treat acute and breakthrough pain.
    • We believe there is a 90% chance the company receives FDA approval on July 27.
    • Zalviso has several advantages over intravenous delivery methods.
    • Obamacare and favorable product pricing should benefit the company in the long term.
  • Activist Investor David Callan Has Been Accumulating Identiv Stock, Here's Why
    Editors' Pick • Tue, Jun. 24 INVE 39 Comments

    Summary

    • These days we hear about shareholder activism almost daily. It is next to impossible to watch CNBC and not hear discussions about some form of activism.
    • Watch Carl Icahn, Dan Loeb, Bill Ackman, George Soros or any of other familiar names that have become famous for challenging public companies and board members.
    • On a much smaller scale and using his own private funds, David Callan has been no exception to that group.
    • He has been successful as an activist in his last four public campaigns to explore strategic alternatives including the sale of the companies.
    • For a refreshing change, Callan is on the other side of the table as an investor in a company he feels will yield large returns over time.
  • Volcano Corp. Is Likely To Be Acquired Soon - Here Is Why
    Thu, Jun. 12 VOLC 28 Comments

    Summary

    • In the area of acquisitions, we've had a solid history of very accurate behavior-based predictions.
    • Although many companies do an excellent job of hiding the progress of a potential acquisition, some clues can still give observant investors an indication that an acquisition is close.
    • However, it can be difficult to make accurate conclusions in that company officers are obligated to keep quiet about these details to obviously avoid insider trading and other SEC violations.
    • We believe we have identified one such company we believe is close to be acquired.
  • The IBB Likely To Move Higher Along With These Biotechs With Catalysts Upcoming
    Mon, Jun. 2 BDSI, IBB, MNKD 35 Comments

    Summary

    • Today, we list five bio pharmaceutical companies with upcoming catalysts. Typically, under normal market conditions, their stocks normally see strong price appreciation.
    • Just because a biotech has an upcoming catalyst event, it does not mean the event will have a positive result.
    • Hedging stock share trades via the option chain by buying puts is one way we protect against downside, should we decide to hold through a catalyst event.
    • Also, we take a look at the iShares Nasdaq Biotechnology ETF index technical chart, which is a very important benchmark that tracks the broader-based Nasdaq biotech sector.
    • Finally, we will go over some macro factors that demonstrate why we believe that U.S. markets will head higher along with biotech for the remainder of the year.
  • Progenics Pharma Poised For A Potential Price Increase Ahead Of June 11 Adcom
    Fri, May. 30 PGNX 5 Comments

    Summary

    • Progenics is expecting a Food and Drug Administration (FDA) Advisory Committee meeting on June 11-12 to decide whether or not to recommend a Supplemental New Drug Application (sNDA).
    • The Relistor sNDA is for a subcutaneous Injection for opioid-induced constipation, or OIC, in patients with chronic pain.
    • If the sNDA is approved by the FDA, Progenics will receive an upfront payment of $50M, along with up to $200M in milestone payments thereafter.
  • Orexigen's Weight Loss Drug Will Be Approved Soon And Will Lead Market - Here Is Why
    Wed, May. 28 OREX 52 Comments

    Summary

    • Coming up on June 10th, 2014, Orexigen Therapeutics expects a Food and Drug Administration (FDA) for it’s weight loss drug NB32 (Contrave).
    • Contrave was initially rejected by the FDA due to a single issue cardiovascular safety concern and requested the company engage a study to provide data to address the concern.
    • Orexigen's "Light Study" Interim analysis was successfully completed on 8900 patients and showed Contrave did not increase the risk of major adverse cardiovascular events (MACE).
    • Due to both the FDA Special Protocol Assessment (SPA) designation and meeting interim requirements for the Light Study, it's virtually certain that Contrave will win FDA approval on June 10th.
    • Because Contrave has safety data that other weight loss drugs do not have, notwithstanding excellent efficacy, we believe it will be the drug of choice prescribed by doctors for patients.
  • Cytokinetics Binary Failure Provides Solid Buying Opportunity
    Thu, May. 1 CYTK 8 Comments

    Summary

    • Small Cap Developmental Biotechs experience on a regular basis what traders call "binary events," which include Phase clinical data releases, Advisory Committee (ADCOM) recommendations, FDA approval decisions, and more.
    • When a company experiences a negative binary event, its stock price normally plummets, and often times gets oversold because investors and traders overreact.
    • We believe we have identified one such small cap biotech we think should make a nice rebound now and in the future.
  • Pozen Is Overvalued, More So Now After Recent FDA Rejection - Here Is Why
    Mon, Apr. 28 POZN 80 Comments

    Summary

    • On Friday, April 25th, Pozen received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)..
    • In a press release, The company cited a manufacturing issue at a 3rd party plant which caused the FDA rejection..
    • In the company PR, it stated that it did not have enough time to address the FDA issues, yet the company had over a year to get it right..
  • High-Risk Small Cap Biotech Keryx Pharma Has Become Overvalued
    Tue, Apr. 1 KERX 45 Comments

    Summary

    • Although we generally look for long plays in the biotechnology sector, certain macroeconomic factors can force us and other investors to look for short ideas.
    • Currently, it’s growing more apparent that money has been shifting, moving out of the pharmaceutical arena.
    • This observation is made obvious by the trend in the $IBB, an exchange traded fund tracking the performance of Nasdaq Biotechnology stocks, which we show below.
  • Following The Smart Money: The Small Cap Biotech Investments Of Randal J. Kirk
    Tue, Mar. 11 FCSC, HALO, SYN 17 Comments

    Summary

    • One of the most tried and true forms of picking the right kind of developmental biotech investment is following those who have success in investing in them.
    • The most successful small cap biotech investors understand that those with a top track record of success tend to repeat this same pattern of success over and over.
    • Randal J. Kirk has a solid record of successful investments in developmental biotech companies. Today, we will look at some of his current investments, and offer commentary on them.
  • 3 Small Cap Biotechs With Near-Term Catalysts
    Thu, Mar. 6 IDRA, INSM, SYN 7 Comments

    Summary

    • Today, we are going to look at 3 companies with near-term binary catalyst events approaching that could have a positive effect on their collective stock prices.
    • Examples of these binary catalyst events include, but are not limited to, Food and Drug Administration (FDA) approval decisions, data releases, and advisory committee recommendations (Adcom).
    • Small cap stock trading can at times, be very volatile, and is not for everyone. As the rewards can be very high, the risk is also very high.
  • Cytokinetics: Small Cap Biotech Investment And Catalyst Trade In Focus
    Wed, Mar. 5 CYTK 7 Comments
  • Synthetic Biologics Under The Radar With Upcoming Multiple Sclerosis Data Catalyst
    Wed, Feb. 19 SYN 28 Comments
  • Significant Upcoming Catalysts For These Biotechs Should Provide Alpha Opportunity
    Fri, Feb. 14 ACRX, ARNA, MNKD 26 Comments
  • Baker Brothers' Holding Cerus Flying Under The Radar With Catalyst Upcoming
    Tue, Feb. 11 CERS 27 Comments
  • Does Accuray's Recent Unusual Bullish Options Activity Signal A Rally In The Stock Soon?
    Tue, Jan. 28 ARAY 16 Comments
  • Sell Watch: Zeltiq Has Become Over-Speculated
    Tue, Jan. 21 ZLTQ 16 Comments
  • Biotechs With Near-Term Catalysts That Should Rally
    Fri, Jan. 10 AMPE, AVNR, CHTP 17 Comments
  • BioPharma Catalyst And Investment Pick In Focus: Progenics
    Tue, Jan. 7 PGNX 11 Comments
  • Small Cap BioPharmas With Near-Term Catalysts
    Fri, Jan. 3 AMRN, APPY, CLDX 48 Comments
  • BioPharma Catalyst And Investment Pick In Focus: Synergy Pharma
    Thu, Jan. 2 SGYP 29 Comments
  • Following Smart Money: Baker Brothers Investments In 2013 And Beyond, Part 2
    Dec. 30, 2013 PCYC, SGYP, VNDA 4 Comments
  • These Small-Cap BioPharma Companies Have Catalysts Upcoming
    Dec. 23, 2013 ACRX, ARIA, INO 13 Comments